Easy-to-use and highly accurate medical software for quantitative assessment of impairments in neurologically injured people.

Informazioni relative al progetto

ReHaptix

ID dell’accordo di sovvenzione: 854147

DOI

10.3030/854147

Progetto chiuso

Data della firma CE 26 Febbraio 2019

Data di avvio 1 Giugno 2019

Data di completamento 30 Settembre 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

REHAPTIX GMBH
Switzerland

Periodic Reporting for period 1 - ReHaptix (Easy-to-use and highly accurate medical software for quantitative assessment of impairments in neurologically injured people.)

Periodo di rendicontazione: 2019-06-01 al 2019-09-30

Sintesi del contesto e degli obiettivi generali del progetto

ReHaptix GmbH is a Swiss company founded in 2013 with the mission to revolutionize the market of neurorehabilitation and monitoring equipment by developing a set of digital tests that objectively measures and remotely monitors the patient’s rehabilitation progress. ReHaptix developed a breakthrough and novel medical software for quantitative digital assessment of physical impairments in neurologically injured people (e.g. stroke, MS and Parkinson’s disease). The team is now working towards developing an upgraded software with a higher number of tests. The key objectives of the development are to finalize software implementation, and to conduct a clinical and market validation.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Within the duration of the project, ReHaptix defined the users’ requirements for product implementation, defined the specifications and reviewed its development plan, and scouted for clinics and hospitals and software developers to support in the validation and product development. Also, the Company established contact with regulatory companies for preparing CE mark. The market segments and opportunities were evaluated, defining the TAM and SAM. ReHaptix established a commercialisation strategy. The Phase 1 feasibility assessment has established that a development plan for ReHaptix software is technically and commercially viable, and that implementation of a commercialisation plan should be pursued. EIC Accelerator funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Nowadays, there are 14M stroke survivors, more than 1.2M Parkinson’s disease patients and 770,000 multiple sclerosis (MS) patients only in Europe. Due to the exponential growth of the world population and the related demographic aging, the number of patients affected by one of these three conditions is rising by 10% yearly. Neurorehabilitation therapy is normally used to treat these diseases. However, there is currently no effective assessment to objectively measure and monitor the rehabilitation progress.
Users that will benefit from ReHaptix's innovation are disabled people, who will be included in the next technological revolution as prioritized also by the EC through its EU Includes programme. ReHaptix's product follows the current growing trends in technological tools for rehabilitation and answers to this EU call. Technology that allows empowerment of patients and better understanding of symptoms evolution is a crucial component of this challenge. Additionally, there is a high incidence rate of neurological disorders in Europe, with a total of 220.7M people suffering from at least one neurological disease during their lifetime. This creates a massive burden on those affected and their social environment as well as on society and healthcare organizations, with total costs reaching €336B a year. ReHaptix's adoption by healthcare institutions can help significantly reducing this socio-economical burden.

image.jpg